Pan-KRAS Inhibitor BI 1701963 clinical trials
Also written BI 1701963.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses Pan-KRAS Inhibitor BI 1701963 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 1701963
- 5
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Boehringer Ingelheim (3) · Amgen (1) · Mirati Therapeutics Inc. (1)
Often tested with
Tested in the same studies.
Sotorasib (1) · Vociprotafib (1) · Batoprotafib (1) · Zeluvalimab (1) · Adagrasib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Pan-KRAS Inhibitor BI 1701963.
- Dec 2026Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Phase 1 · Amgen
- Mar 2027A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Phase 1 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses Pan-KRAS Inhibitor BI 1701963 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Active, not recruitingPhase 1Boehringer IngelheimNCT04111458Written as BI 1701963
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as BI 1701963
- Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedPhase 1Mirati Therapeutics Inc.NCT04975256Written as BI 1701963
- A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])TerminatedPhase 1Boehringer IngelheimNCT04835714Written as BI 1701963
- A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) MutationTerminatedPhase 1Boehringer IngelheimNCT04627142Written as BI 1701963